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The risk of venous thromboembolic events is thought to
be highest in patients with membranous nephropathy. This
association has been recently questioned, and it is not known
whether this simply reflects the severity of proteinuria. To
better understand the relationship between histologic
diagnosis and the risk of venous thromboembolic events we
evaluated patients in the Toronto Glomerulonephritis
Registry. Of 1313 patients with idiopathic glomerulonephritis,
395 were diagnosed with membranous nephropathy, 370
with focal segmental glomerulosclerosis (FSGS), and 548 with
immunoglobulin-A nephropathy (IgAN). Risk factors were
evaluated by Cox proportional hazards for 53 image-
confirmed venous thromboembolic events in 44 patients
during a median follow-up of 63 months. The risk was
highest in patients with membranous nephropathy and FSGS
(hazard ratios of 22 and 7.8, respectively) referenced to
patients with IgAN. Following adjustment for gender, cancer
history, proteinuria, and serum albumin by multivariable
analysis, the histologic subtype remained an independent
risk for venous thromboembolic events. This risk was still
highest in patients with membranous nephropathy followed
by FSGS with adjusted hazard ratios of 10.8 and 5.9,
respectively. Thus, in this large cohort, histologic diagnosis
was an independent risk factor for venous thromboembolic
events. Further studies are needed to discover mechanisms
responsible for this high risk in patients with membranous
nephropathy.
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Complications of the nephrotic syndrome are an important
cause of morbidity in patients with idiopathic glomerulone-
phritis (GN).1 One such complication is venous thromboem-
bolic events (VTEs) including deep and renal vein
thromboses (RVTs), as well as pulmonary emboli. The
reported risk of VTEs in patients with nephrotic syndrome is
highly variable, due to diverse patient populations and
variable screening practices. The risk of VTE is not well
defined, and is reported to range from 3 to 48%, depending
upon the site of the VTE and the intensity of diagnostic
screening.2,3 Given the potentially significant morbidity and
mortality associated with these events,4 a better under-
standing of the frequency of clinically detected VTEs would
help to guide therapy.
The nephrotic syndrome is considered to be a thrombo-
philic milieu due to a variety of elements including
measurable changes in coagulation factors due to protein
loss in the urine, altered platelet activity, intravascular
volume contraction, venous stasis accompanying edema,
and chronic inflammation.5 Historically, the cause of the
underlying glomerular disease was proposed to be an
important risk for VTE, with membranous nephropathy
(MN) implicated as a risk factor for these events.3 However,
studies that implicated MN as a risk factor for VTE primarily
diagnosed asymptomatic thrombotic events on routine
screening of uncertain clinical impact; did not adjust for
the level of proteinuria or hypoalbuminemia, population age,
or cancer; and did not compare with disease-specific
controls.5–9 In contrast to historical tenets, the largest study
to address this topic showed an annual incidence rate of VTE
in MN similar to that seen in other glomerular diseases.10
Therefore, the disease-specific risk of VTE in patients with
idiopathic GN remains an area of significant uncertainty.
Accordingly, we sought to define the disease-specific risk
of clinically evident VTEs in patients with idiopathic GN
after adjusting for thrombophilic risk factors common in
glomerular diseases such as proteinuria, hypoalbuminemia,
and malignancy. We studied a large cohort of patients with
idiopathic immunoglobulin-A nephropathy (IgAN), focal
and segmental glomerulosclerosis (FSGS), and MN, who
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were followed up longitudinally in the Toronto Glomerulo-
nephritis Registry in order to better understand the disease-
specific risk of VTE in patients with idiopathic GN.
RESULTS
Patient characteristics
The study cohort comprised 1313 patients, including 370
subjects with FSGS, 548 with IgAN, and 395 with MN.
Reasons for exclusion from the study are outlined in
Supplementary Figure S1 online. Baseline characteristics are
described in Table 1. The cohort comprised 63% male
patients, followed up for a median of 63 months with
baseline proteinuria of 3.1 g/day and albumin of 32.9 g/l.
Several clinical parameters differed across diagnostic
categories: patients with MN tended to be older, were more
likely men and of Caucasian background, had more severe
proteinuria and hypoalbuminemia, and better renal function
at the time of first presentation. Cancer, either before
presentation or during the follow-up period, occurred in
3.7% of patients. There was a trend toward a higher number
of cancer events in patients with MN; however, this did not
reach statistical significance (P¼ 0.06 across groups).
The distribution of proteinuria at presentation and during
the follow-up (the time-averaged (TA) proteinuria) across
diagnostic categories is illustrated in Figure 1. A greater
proportion of patients with MN had high-grade proteinuria
(48 g/day) at presentation, and sustained over time,
compared with other GN subtypes (Po0.0001).
Venous thromboembolic events: frequency
There were 53 VTEs in 44 patients, with the types of events
described in Table 2. A greater proportion of patients with
MN developed VTEs, compared with FSGS or IgAN (7.85%
vs. 2.97% vs. 0.36%, respectively, Po0.0001). Even when
isolated RVT was excluded from the analysis, a larger
proportion of patients with MN experienced a VTE
compared with patients with FSGS or IgAN (4.8% vs. 2.7%
vs. 0.36%, Po0.0001).
Venous thromboses occurred at a median of 272 days after
first presentation. Overall, 57% of VTEs occurred within 1
year and 70% within 2 years of presentation. The VTEs
tended to occur closer to the time of GN diagnosis in patients
with MN; however, there was a wide range in the timing of
the event, and this did not reach statistical significance. The
risk of VTE over time is illustrated in the Kaplan–Meier curve
in Figure 2. The risk of thrombosis during the follow-up
period differed across all three groups, with the lowest risk in
IgAN patients and the highest in MN patients (Po0.0001
across groups). The characteristics of patients at the time of
VTE according to underlying GN diagnosis are summarized
in Table 3; at the time of the VTE, patients with MN
Table 1 | Baseline (within 6 months of presentation) and longitudinal characteristics
Overall FSGS IgAN MN P-value
Number of patients 1313 370 548 395
Length of follow-up (months; median (LQ, UQ)) 63.0 (33.3, 108.0) 67.8 (35.9, 110.1) 62.6 (33.4, 105.5) 59.6 (30.3, 104.9) 0.3
Age at presentation (years; mean (s.d.)) 42.2 (15.2) 42.5 (15.8) 38.1 (13.1) 45.6 (15.6) o0.0001
Sex (% male) 63.1 62.4 61.3 66.1 0.3
Race (%) o0.0001
Caucasian 67.6 69.0 58.6 78.5
African American 5.6 9.0 3.2 5.4
Asian 15.3 11.0 26.6 4.0
Other 11.6 11.0 11.6 12.0
Estimated CrCl at presentation (ml/min per 1.73m2; mean (s.d.)) 74.4 (30.0) 71.6 (30.9) 73.5 (29.2) 78.4 (30.0) 0.0007
Proteinuria at presentation (g/day; median (LQ, UQ)) 3.1 (1.5, 6.5) 3.7 (1.8, 6.8) 1.6 (0.8, 2.9) 5.6 (3.3, 9.9) o0.0001
TA proteinuria during follow-up (g/day; median (LQ, UQ)) 2.6 (1.4, 4.6) 3.3 (1.8, 4.9) 1.8 (0.8, 2.9) 3.9 (2.0, 6.5) o0.0001
Albumin at presentation (g/l; mean (s.d.)) 32.9 (9.1) 33.1 (9.7) 38.2 (6.6) 26.8 (7.1) o0.0001
TA albumin during follow-up (g/l; mean (s.d.)) 36.5 (6.2) 36.6 (6.8) 39.1 (4.5) 33.0 (6.0) o0.0001
Cancer history prior to or during follow-up period (number (%)) 48 (3.7) 14 (3.8) 13 (2.4) 21 (5.3) 0.06
Abbreviations: FSGS, focal segmental glomerulosclerosis; IgAN, immunoglobulin-A nephropathy; LQ, lower quartile; MN, membranous nephropathy; TA, time averaged;
UQ, upper quartile.
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Figure 1 |Percentage of patients with each category of
proteinuria at presentation, and time-averaged proteinuria
(TA proteinuria). FSGS, focal segmental glomerulosclerosis; IgAN,
immunoglobulin-A nephropathy; MN, membranous nephropathy.
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and FSGS were hypoalbuminemic and had nephrotic-range
proteinuria.
Venous thromboembolic events: risk factors
The results of univariable analyses to identify clinical features
associated with the development of VTE are shown in
Table 4. The underlying histological diagnosis was closely
associated with VTE risk; the risk was highest in patients with
MN (unadjusted hazard ratio 22.0, 95% confidence interval
5.3–92.1, Po0.01) and FSGS (hazard ratio 7.8, 95%
confidence interval 1.7–35.2, Po0.01) compared with IgAN
(reference group). Male sex, proteinuria at presentation, TA
proteinuria, albumin at presentation, and TA albumin were
all associated with VTEs (see Table 4).
Proteinuria at presentation and TA proteinuria, when
expressed as either continuous (log transformed) or categor-
ical variables, were both significantly associated with VTEs,
as were albumin at presentation and TA albumin. The risk of
VTE was directly proportional to the severity of proteinuria
and inversely related to the albumin level, for both at
presentation and TA values.
A diagnosis of cancer at any time during the patient course
was found to be a risk factor for the development of VTE in
this cohort. There were a total of 48 cancers in the cohort.
Approximately 11% of the patients with VTE (n¼ 5 of 44
patients with VTE) had a diagnosis of cancer prior to
diagnosis or during follow-up, compared to 3.7% in the total
cohort.
Age and self-reported race were not associated with
thrombotic events (data not shown).
To determine the independent relationship between
histological diagnoses and VTE risk, a multivariable model,
including the covariates such as male sex, cancer history,
proteinuria, and albumin levels, was considered. As indicated
in Table 5, sex and serum albumin were associated with
increased risk of VTE, whereas cancer and proteinuria were
not. Similar results were obtained when considering TA
albumin and TA proteinuria (data not shown). Even after
adjustment for these important clinical variables, the under-
lying histological diagnosis remained independently asso-
ciated with thrombotic events, with the higher risk in MN
and FSGS compared with IgAN (adjusted hazard ratio¼ 10.8,
P¼ 0.002, for patients with MN and adjusted hazard
ratio¼ 5.9, P¼ 0.02, for patients with FSGS).
DISCUSSION
VTEs are a potentially life-threatening complication of the
nephrotic syndrome. The risk of VTE has traditionally been
thought to be highest in patients with MN; however, it is not
clear whether this disease-specific risk is independent of
clinical variables such as patient age or degree of proteinuria.
In this study, we sought to determine whether the underlying
histological diagnosis is an independent risk factor for the
development of clinically evident VTE.
We have shown that the risk of clinically evident VTE in
patients with idiopathic GN is closely related to the
underlying histological diagnosis, with the highest risk in
MN, the lowest in IgAN, and an intermediate risk in FSGS.
The higher frequency of VTEs was not uniquely attributable
to a higher frequency of RVT events; a higher frequency of
VTEs was observed in patients with MN even when RVTs
were excluded. In our cohort, when considered in isolation,
both proteinuria and hypoalbuminemia increased the risk of
VTE; however, the disease-specific risk of VTE was indepen-
dent of the degree of proteinuria, serum albumin levels, and
cancer history. Although patients with MN were more likely
to have higher levels of proteinuria and lower albumin levels,
as well as high rates of cancer, these differences did not fully
account for differences in VTE risk.
Table 2 | The number and nature of VTEs
Overall, N=1313 FSGS, N=370 IgAN, N=548 MN, N=395 P-value
Patients with a VTE (number (%)) 44 (3.4) 11 (3.0) 2 (0.4) 31 (7.9) o0.0001
Number of VTEs of each type
DVT 10 4 1 5
PE 20 8 1 11
RVT 19 2 0 17
Other 4 0 0 4
Days to first VTE (median (LQ, UQ)) 272 (0, 1080) 1094 (401, 1604) 453 (363, 542) 151 (0, 447) 0.07
Abbreviations: DVT, deep vein thrombosis; FSGS, focal segmental glomerulosclerosis; IgAN, immunoglobulin-A nephropathy; LQ, lower quartile; MN, membranous
nephropathy; PE, pulmonary embolism; RVT, renal vein thrombosis; UQ, upper quartile; VTE, venous thromboembolic event.
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Figure 2 | The risk of VTE over time by type of GN (Po0.0001
across groups). FSGS, focal segmental glomerulosclerosis;
GN, glomerulonephritis; IgA, immunoglobulin A; VTE, venous
thromboembolic event.
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Data regarding the disease-specific risk of VTE in patients
with the nephrotic syndrome are divergent. Historically, MN
has been associated with a particularly high risk of VTE. This
was supported by studies that used screening renal veno-
grams, and a substantial proportion of VTEs captured in the
patient population were asymptomatic RVTs; in these studies,
the risk of VTE was reported to be as high as 86%.5–7,9,11
However, the clinical impact of these asymptomatic VTEs is
unclear. Furthermore, not all studies uniformly found a
similarly high frequency of VTE in MN.3 In addition,
previous studies did not adjust for proteinuria or albumin
level; therefore, the question of the independent disease-
specific risk of VTE remained unanswered.5,11,12 The largest
study to date, to address disease-specific risk included 298
patients with nephrotic-range proteinuria, of whom 157 had
idiopathic primary GN.10 In this study, there was no
observed difference in the incidence of VTE between MN,
FSGS, and minimal change disease, and only proteinuria
above 8.2 g/day was associated with increased VTE risk.10
Our study findings differ likely because of the fact that our
large sample size of over 1300 patients may be better powered
to detect disease-specific differences in risk.
Our study results prompt two important questions for
future consideration. First, why is MN independently
associated with a particularly high VTE risk? Next, how
could these data inform decisions regarding prophylactic
anticoagulation?
Table 3 | Description of patients with (VTE+) and without (VTE) VTEs
FSGS, N=11 events MN, N=31 events IgAN, N=2 events
VTE+ VTE VTE+ VTE VTE+ VTE
Albumin at presentation (g/l) 26.1 (8.7) 33.2 (9.7) 21.9 (6.1) 27.2 (7.1) 40, 46a 38.2 (6.6)
TA albumin over entire follow-up (g/l) 33.3 (5.4) 36.7 (6.8) 32.7 (6.1) 33.0 (5.9) 44.0, 46.0 39.1 (4.5)
Proteinuria at presentation (g/day) 8.2 (3.0, 13.7) 3.6 (1.8, 6.7) 6.5 (4.4, 11.2) 5.6 (3.2, 9.7) 3.5, 0.5a 1.6 (0.8, 2.9)
TA proteinuria over entire follow-up (g/day) 5.9 (4.1, 7.0) 3.1 (1.8, 4.9) 4.9 (2.7, 9.3) 3.7 (1.9, 6.5) 0.5, 2.8 1.8 (0.8, 2.9)
Albumin at time of VTE (g/l) 32.8 (8.2) NA 25.5 (7.4) NA 40.0b NA
Proteinuria at time of VTE (g/day) 6.2 (3.9, 10.7) NA 9.8 (3.7, 11.7) NA 3.4, 0.5 NA
Days to first VTE 1094 (401, 1604) NA 151 (0, 447) NA 363, 542 NA
Abbreviations: FSGS, focal segmental glomerulosclerosis; IgAN, immunoglobulin-A nephropathy; MN, membranous nephropathy; NA, not applicable; TA, time averaged; VTE,
venous thromboembolic event.
Data are provided as median (lower quartile, upper quartile) or mean (standard deviation), except for IgAN where individual data are provided, as there were only 2 VTEs.
aValues presented are first available.
bAlbumin at time of VTE was not available for one patient.
Table 4 | Univariable analyses: clinical variables associated
with risk of venous thromboembolic events
HR 95% CI P-value
Underlying disease 0.0001
IgAN Reference
FSGS 7.8 1.7–35.2 0.008
MN 22.0 5.3–92.1 o0.0001
Male sex 2.6 1.2–5.6 0.01
Proteinuria at presentation by categories 0.0003
o1 g/day Reference
1–3.5 g/day 3.0 0.4–24.4 0.3
3.6–8 g/day 8.2 1.1–62.8 0.04
48 g/day 17.0 2.3–127.6 0.006
TA proteinuria by categories 0.0002
o1 g/day Reference
1–3.5 g/day 5.7 0.8–42.8 0.09
3.6–8 g/day 13.3 1.8–99.9 0.01
48 g/day 25.3 3.2–198.7 0.002
Albumin at presentation by categories o0.0001
438 g/l Reference
29–38 g/l 4.3 0.5–37.1 0.2
o29 g/l 27.7 2.8–203.9 o0.0001
TA albumin by categories 0.002
439 g/l Reference
35–39 g/l 3.4 1.3–8.9 0.01
o35 g/l 5.5 2.2–13.5 o0.0001
Abbreviations: CI, confidence interval; FSGS, focal segmental glomerulosclerosis;
HR, hazard ratio; IgAN, immunoglobulin-A nephropathy; MN, membranous
nephropathy; TA, time averaged.
Albumin and proteinuria metrics are given both as continuous variables and by
categories.
Table 5 |Multivariable analysis of risk of venous
thromboembolism
HR 95% CI P-value
Male sex 2.4 1.1–5.3 0.02
Cancer history 2.4 0.9–6.3 0.07
Albumin at presentation 0.02
438 g/l Reference
29–38 g/l 2.7 0.3–23.9 0.4
o29 g/l 9.6 1.2–76.4 0.03
Proteinuria at presentation 0.7
o1 g/day Reference
1–3.5 g/day 1.6 0.2–13.9 0.6
3.6–8 g/day 1.9 0.2–14.9 0.5
48 g/day 2.6 0.3–20.2 0.4
Underlying disease 0.006
IgAN Reference
FSGS 5.9 1.3–27.9 0.02
MN 10.8 2.4–49.4 0.002
Abbreviations: CI, confidence interval; FSGS, focal segmental glomerulosclerosis;
HR, hazard ratio; IgAN, immunoglobulin-A nephropathy; MN, membranous
nephropathy.
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The mechanisms responsible for the increased VTE risk
require further study and elucidation. The nephrotic
syndrome itself is purported to cause changes in hemostatic
factors that favor thrombosis, including increased fibrinogen
and coagulation factor levels and decreased antithrombin III,
protein C and S, and plasminogen levels.4 However, these
findings are inconsistent, and less is known about mecha-
nisms by which MN may specifically place patients with
nephrotic syndrome at higher risk of VTE. Given that the
absolute quantity of proteinuria may not independently
explain the VTE risk, the nature of the proteinuria may differ
between types of GN. The particular molecular weight of
proteins lost in patients with MN may result in disease-
specific alterations in proteins that affect susceptibility to
thrombosis.13 Antibodies to a-enolase have been observed in
patients with MN, and these may have antifibrinolytic
activity.14,15 There is also a suggestion that factor V Leiden
mutation may be associated with MN, providing a second
hypercoagulable risk factor in addition to the nephrotic
syndrome.16 A relationship between antibodies to the M-type
phospholipase receptor (PLA2R) and VTE risk also requires
further exploration.17
The next logical stage in analysis is an evaluation of the
risks and benefits of prophylactic anticoagulation in patients
with GN. Our data suggest several characteristics that may
identify patients with proteinuric GN who may be at highest
risk of thrombosis, including male gender, significant
hypoalbuminemia, and an underlying histological diagnosis
of MN. The timing of VTE in MN appeared to be earlier than
in those with FSGS (see Table 2), supporting the need for
additional analyses to identify disease-specific time periods of
highest thrombosis risk. These could then be used in a formal
decision analysis to help guide the use of prophylactic
anticoagulation.
Several considerations regarding how our study design
may have affected our findings merit comment. Patients did
not undergo predefined screening tests to diagnose venous
thrombotic events. It is therefore possible that patients with
more severe nephrotic syndrome or those with a diagnosis of
MN may have been more aggressively investigated for VTEs
because of their higher perceived risk. One might expect this
to have the most impact with respect to detection of RVT;
indeed, VTE frequency was disproportionately high even
when RVTs were excluded from the analysis. Next, there was
a trend suggesting earlier thrombotic events in patients with
MN, which needs to be considered in the context of our
inclusion of patients with at least 1 year of follow-up in our
analysis. We chose 1 year of follow-up in order to assure
adequate time to detect events across all GN subtypes, and to
accrue sufficient clinical data to identify risk factors
associated with VTE. This may have biased our results
toward diagnosing fewer events, potentially underestimating
the increased risk of VTE in MN. We verified that this was
not likely to be a concern, given that only two VTEs were
documented in patients with MN who had o1 year of
follow-up (see Materials and Methods). In addition, an
underestimation of the risk of events would not necessarily
alter our findings of the risk factors associated with VTE.
Finally, despite the large size of our cohort and the long
follow-up period, there were relatively few events, which does
limit the ability to identify predisposing risk factors. In
conclusion, this underscores the rarity of clinically evident
venous thrombotic events in this patient population and the
need to identify those patients at highest risk to target clinical
interventions.
In summary, we have shown that patients with MN have a
greater risk of VTE compared with those with FSGS or IgAN,
even after adjustment for differences in degree of proteinuria,
hypoalbuminemia, and malignancy. Further research is
required to identify reasons for the disease-specific risk of
VTE in patients with MN.
MATERIALS AND METHODS
Description of the cohort
Since 1974, all patients with biopsy-proven idiopathic GN in the
greater Toronto area have been enrolled in the Toronto Glomer-
ulonephritis Registry.18 Information is collected prospectively by
registrars as of the time of first clinical presentation, and includes
demographics, baseline and developing comorbidities, clinical and
laboratory parameters, and medication use.
We considered all patients in the Toronto GN Registry with
idiopathic IgAN, FSGS, and MN for enrolment in our cohort. We
excluded those patients with secondary causes of GN, who were
younger than 16 years of age at presentation, had incomplete clinical
data, or less than 12 months of follow-up. We included patients with
a spectrum of disease severity, including those who had subne-
phrotic proteinuria, to more completely describe the risk of VTE
associated with the underlying histological type of disease. The
12-month period was chosen to ensure that patients were followed
up long enough to capture VTEs. There were 2790 patients
considered for our cohort, of whom 1477 were excluded resulting
in a cohort of 1313 patients, including 370 with FSGS, 548 with
IgAN, and 395 with MN. Supplementary Figure S1 online shows the
derivation of the cohort and reasons for exclusion. We determined
that only two VTEs were detected in 94 MN patients with o1 year
of follow-up, supporting the fact that restricting our analyses to
patients with longer follow-up would not substantially under-
estimate the frequency of events.
Definitions
The start of the follow-up period was defined as the time of the first
assessment with available clinical and laboratory data. This may
have preceded the date of renal biopsy. Baseline parameters were
taken as the first available within 6 months of the start of the follow-
up period. Secondary causes of GN were defined as the presence of
systemic lupus erythematosis, hepatitis B, hepatitis C, HIV, or other
coexistent glomerular diseases on biopsy (such as diabetes).
Proteinuria was measured in 24-h urine collections. The follow-
up period was broken into 6-month blocks, the average proteinuria
during each block was determined, and the mean of all such values
was termed the TA proteinuria, and meant to reflect the burden of
proteinuria during the follow-up period. Similarly, the TA albumin
levels (TA albumin) were calculated. Creatinine clearance was
estimated from the Cockroft-Gault formula and standardized to
body surface area (ml/min per 1.73m2).19 Race was self-reported.
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Comorbidities were prospectively collected by the registrars during
routine chart reviews.
Outcomes
We reviewed the longitudinal follow-up data of patients within the
Toronto Glomerulonephritis Registry and extracted all venous
thrombotic events. Routine screening for asymptomatic events was
not performed, although some RVTs were detected on routine pre-
biopsy ultrasound tests. Most events were clinically symptomatic,
prompting further investigations, and were confirmed by imaging
modalities. Pulmonary embolus was confirmed by pulmonary
angiography, ventilation–perfusion scans, or computed tomography;
deep vein thrombosis by ultrasound; and RVT by ultrasound,
computed tomography, or percutaneous renal venograms. To ensure
that cases were not missed, the records for all patients on warfarin
were identified for repeat review to determine whether VTE may
have been the indication for anticoagulation.
Statistical analyses
Data were analyzed using Microsoft Excel and SAS software.
Normally distributed variables were described as mean standard
deviation and compared across groups using analysis of variance.
Nonparametric variables were described as median (lower quartile
and upper quartiles), and compared using the Kruskal–Wallis test.
Categorical variables were compared using the w2-test. All P-values
are two tailed, with o0.05 considered statistically significant.
The time to event was measured as the time from the start of the
follow-up period to the documentation of a VTE. Differences in
event-free survival were determined using the Cox proportional
hazards test.
The Cox proportional hazards test was used to identify clinical
variables associated with the risk of VTE. Covariates considered
included histological diagnosis, age, sex, self-reported race, cancer,
proteinuria at presentation, TA proteinuria, albumin at presenta-
tion, and TA albumin. Because proteinuria is not normally
distributed, it was analyzed as a log-transformed variable. All
variables found to be significantly associated with VTE risk by
univariable models were included in a multivariable model.
However, proteinuria at presentation was found to be highly
correlated with TA proteinuria; similarly, albumin at presentation
was found to be highly correlated with TA albumin. Therefore, we
chose to include proteinuria and albumin at presentation in our
multivariable models. These were expressed as categorical variables
to account for missing values, which were not associated with VTE
risk (P¼ 0.34 for missing albumin and P¼ 0.31 for missing
proteinuria). Multivariable analysis was repeated using TA albumin
and TA proteinuria as covariates instead of values at presentation,
with similar results (data not shown).
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